The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization.
The primary objective of this study is to evaluate the efficacy of the second-generation antihistamine, loratadine, as prophylaxis for filgrastim (i.e., Neupogen, Zarxio) induced bone pain during stem cell mobilization in multiple myeloma patients.
The secondary objectives are to (1) examine the frequency and quantity of supportive analgesic medications needed in addition to loratadine or placebo for filgrastim induced bone pain and (2) identify risk factors associated with developing filgrastim induced bone pain.
Ill-Defined Sites
Multiple Myeloma
Pegfilgrastim
Chemotherapy multiple agents systemic
- RWJBarnabas Health
- Robert Wood Johnson University Hospital, New Brunswick
- Rutgers University
Inclusion Criteria: - Patient must be able to provide informed consent - Patients with confirmed diagnosis of multiple myeloma - Able to swallow and retain oral medication - All ethnic groups are eligible Exclusion Criteria: - Non-English speaking person - Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant - Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds - Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study - On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.